JP2014530603A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530603A5 JP2014530603A5 JP2014534726A JP2014534726A JP2014530603A5 JP 2014530603 A5 JP2014530603 A5 JP 2014530603A5 JP 2014534726 A JP2014534726 A JP 2014534726A JP 2014534726 A JP2014534726 A JP 2014534726A JP 2014530603 A5 JP2014530603 A5 JP 2014530603A5
- Authority
- JP
- Japan
- Prior art keywords
- vivo method
- hiv
- cells
- endogenous
- transgene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 24
- 108700019146 Transgenes Proteins 0.000 claims description 14
- 230000036436 anti-hiv Effects 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 4
- 101150017501 CCR5 gene Proteins 0.000 claims description 4
- 108010076039 Polyproteins Proteins 0.000 claims description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 4
- 102000038627 Zinc finger transcription factors Human genes 0.000 claims description 4
- 108091007916 Zinc finger transcription factors Proteins 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 108010004483 APOBEC-3G Deaminase Proteins 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 2
- 101150066398 CXCR4 gene Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 206010010144 Completed suicide Diseases 0.000 claims description 2
- 102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 claims description 2
- 108010083930 HIV Receptors Proteins 0.000 claims description 2
- 102000006481 HIV Receptors Human genes 0.000 claims description 2
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 claims description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 claims description 2
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 claims description 2
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 claims description 2
- 235000011449 Rosa Nutrition 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544101P | 2011-10-06 | 2011-10-06 | |
| US61/544,101 | 2011-10-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530603A JP2014530603A (ja) | 2014-11-20 |
| JP2014530603A5 true JP2014530603A5 (enExample) | 2015-10-08 |
Family
ID=48044158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534726A Pending JP2014530603A (ja) | 2011-10-06 | 2012-10-04 | Ｈｉｖ感染を制御するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20130171732A1 (enExample) |
| EP (1) | EP2764102A4 (enExample) |
| JP (1) | JP2014530603A (enExample) |
| AU (1) | AU2012318562A1 (enExample) |
| CA (1) | CA2849920A1 (enExample) |
| HK (1) | HK1200491A1 (enExample) |
| WO (1) | WO2013052681A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2852955C (en) * | 2011-10-27 | 2021-02-16 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| RU2721275C2 (ru) | 2012-12-12 | 2020-05-18 | Те Брод Инститьют, Инк. | Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии |
| EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| EP3725885A1 (en) | 2013-06-17 | 2020-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| CA2915837A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| EP3011029B1 (en) | 2013-06-17 | 2019-12-11 | The Broad Institute, Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| WO2014204729A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
| BR112015031608A2 (pt) | 2013-06-17 | 2017-08-22 | Massachusetts Inst Technology | Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos |
| AU2014281030B2 (en) | 2013-06-17 | 2020-07-09 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
| CA2930877A1 (en) * | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| MX374529B (es) | 2013-12-12 | 2025-03-06 | Broad Inst Inc | Suministro, uso y aplicaciones terapeuticas de sistemas y composiciones crispr-cas para edicion del genoma. |
| EP4219699A1 (en) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| EP3080261B1 (en) | 2013-12-12 | 2019-05-22 | The Broad Institute, Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
| EP3080257A1 (en) | 2013-12-12 | 2016-10-19 | The Broad Institute Inc. | Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders |
| CN106536729A (zh) | 2013-12-12 | 2017-03-22 | 布罗德研究所有限公司 | 使用粒子递送组分靶向障碍和疾病的crispr‑cas系统和组合物的递送、用途和治疗应用 |
| WO2016014837A1 (en) * | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Gene editing for hiv gene therapy |
| EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
| EP3702456A1 (en) | 2014-12-24 | 2020-09-02 | The Broad Institute, Inc. | Crispr having or associated with destabilization domains |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| WO2016205613A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Crispr enzyme mutations reducing off-target effects |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1352960A1 (en) * | 2002-04-12 | 2003-10-15 | Viruvation B.V. | Antiviral therapy on the basis of RNA interference |
| US20100055793A1 (en) * | 2005-07-25 | 2010-03-04 | Johns Hopkins University | Site-specific modification of the human genome using custom-designed zinc finger nucleases |
| CN101273141B (zh) * | 2005-07-26 | 2013-03-27 | 桑格摩生物科学股份有限公司 | 外源核酸序列的靶向整合和表达 |
| US20080003681A1 (en) * | 2006-06-28 | 2008-01-03 | Mahalaxmi Gita Bangera | Methods for altering cellular susceptibility to infection |
| US8563314B2 (en) * | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| US8193161B2 (en) * | 2008-06-09 | 2012-06-05 | New York Medical College | Compositions comprising cardiac stem cells overexpressing specific micrornas and methods of their use in repairing damaged myocardium |
| CA2755192C (en) * | 2009-03-20 | 2018-09-11 | Sangamo Biosciences, Inc. | Modification of cxcr4 using engineered zinc finger proteins |
| DK2462230T3 (en) * | 2009-08-03 | 2015-10-19 | Recombinetics Inc | METHODS AND COMPOSITIONS FOR TARGETED RE-MODIFICATION |
| CN102071219B (zh) * | 2010-11-05 | 2014-03-12 | 冯小荣 | 改腺载体及其在艾滋病预防和治疗药物中的应用 |
-
2012
- 2012-10-04 AU AU2012318562A patent/AU2012318562A1/en not_active Abandoned
- 2012-10-04 US US13/645,175 patent/US20130171732A1/en not_active Abandoned
- 2012-10-04 HK HK15101108.0A patent/HK1200491A1/xx unknown
- 2012-10-04 JP JP2014534726A patent/JP2014530603A/ja active Pending
- 2012-10-04 EP EP12838704.0A patent/EP2764102A4/en not_active Withdrawn
- 2012-10-04 WO PCT/US2012/058775 patent/WO2013052681A1/en not_active Ceased
- 2012-10-04 CA CA 2849920 patent/CA2849920A1/en not_active Abandoned
-
2015
- 2015-05-28 US US14/724,250 patent/US20150267223A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530603A5 (enExample) | ||
| JP2016539627A5 (enExample) | ||
| Sun et al. | Advances in the techniques and methodologies of cancer gene therapy | |
| Deering et al. | Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines | |
| US12442016B2 (en) | Scarless genome editing through two-step homology directed repair | |
| WO2016073955A3 (en) | Cells lacking b2m surface expression and methods for allogeneic administration of such cells | |
| Kallen et al. | A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs | |
| AU2025217410A1 (en) | Allograft tolerance without the need for systemic immune suppression | |
| US12485187B2 (en) | Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM171 | |
| MX2024006041A (es) | Celulas t modificadas y metodos para hacer y usar las mismas. | |
| MX349138B (es) | Variones de virus adeno-asociados con capside variante y sus metodos de uso. | |
| AR092317A1 (es) | Vectores virales para el tratamiento de distrofia retiniana | |
| Sioud et al. | Silencing of indoleamine 2, 3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients | |
| MX2021009554A (es) | Produccion de virus en cultivos celulares. | |
| JP2024519524A (ja) | 疾患の処置のために有用なレンチウイルスベクター | |
| WO2016010155A1 (ja) | 抗原特異的ｔ細胞受容体遺伝子を有する多能性幹細胞の製造方法 | |
| Maring et al. | Myocardial regeneration via progenitor cell‐derived exosomes | |
| Murugesan et al. | Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells | |
| JP2014515258A5 (enExample) | ||
| Yao et al. | Mesenchymal stem cells as novel micro‐ribonucleic acid delivery vehicles in kidney disease | |
| WO2012159120A3 (en) | Gene therapy based strategy for treating hiv | |
| Wang et al. | Engineering hematopoietic stem cells toward a functional cure of human immunodeficiency virus infection | |
| Freitas et al. | Advances in Engineering Myeloid Cells for Cell Therapy Applications | |
| Stevens et al. | A temperature-sensitive and less immunogenic Sendai virus for efficient gene editing | |
| Jun et al. | Recipient dendritic cells modified by RNA interference targeting CD80 and CD86 elicit T cell hyporesponsiveness via enhanced T cell apoptosis |